Prespecified After-effects Elicited from Robotic Force Fields
暂无分享,去创建一个
[1] R. Castelluccio. [Introduction to neuropsychopharmacology]. , 1961, El Dia medico.
[2] M. Lorr,et al. Manual for the Profile of Mood States , 1971 .
[3] H. Norris. The action of sedatives on brain stem oculomotor systems in man. , 1971, Neuropharmacology.
[4] I. Magnussen,et al. The effects of aromatic amino acid decarboxylase inhibitors on plasma concentrations of 5-hydroxytryptophan in man. , 2009, Acta pharmacologica et toxicologica.
[5] S. Yen,et al. A mid-day surge in cortisol levels. , 1979, The Journal of clinical endocrinology and metabolism.
[6] F. Nielsen‐Kudsk,et al. Pharmacokinetics of intravenously administered L-5-hydroxytryptophan in man. , 2009, Acta pharmacologica et toxicologica.
[7] G. Brandenberger,et al. Diurnal cortisol peaks and their relationships to meals. , 1982, The Journal of clinical endocrinology and metabolism.
[8] F. Holsboer. The dexamethasone suppression test in depressed patients: clinical and biochemical aspects. , 1983, Journal of steroid biochemistry.
[9] A. Steiger,et al. CORTICOTROPIN-RELEASING-FACTOR INDUCED PITUITARY-ADRENAL RESPONSE IN DEPRESSION , 1984, The Lancet.
[10] W. Vale,et al. Effect of synthetic ovine corticotropin-releasing factor: Prolonged duration of action and biphasic response of plasma adrenocorticotropin and cortisol , 1984 .
[11] S. Lamberts,et al. Corticotropin-releasing factor (ovine) and vasopressin exert a synergistic effect on adrenocorticotropin release in man. , 1984, The Journal of clinical endocrinology and metabolism.
[12] F. Holsboer,et al. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. , 1984, The New England journal of medicine.
[13] K. Shizume,et al. EFFECT OF METOCLOPRAMIDE ON PLASMA VASOPRESSIN IN MAN , 1984, Clinical endocrinology.
[14] W. Vale,et al. Arginine vasopressin potentiates adrenocorticotropin release induced by ovine corticotropin-releasing factor. , 1984, The Journal of clinical investigation.
[15] C. Marchesi,et al. Different effects of metoclopramide and domperidone on arginine-vasopressin secretion in man. , 1986, British journal of clinical pharmacology.
[16] A. Caiazza,et al. MUSCARINIC CHOLINERGIC, BUT NOT SEROTONINERGIC MEDIATION OF ARGININE VASOPRESSIN RESPONSE TO METOCLOPRAMIDE IN MAN , 1989, Clinical endocrinology.
[17] P. Cowen,et al. Mediation of ACTH and prolactin responses to 5-HTP by 5-HT2 receptors. , 1990, European journal of pharmacology.
[18] F. Mitchelson. Pharmacological agents affecting emesis. A review (Part I). , 1992, Drugs.
[19] R. Dahl,et al. Neuroendocrine response to L-5-hydroxytryptophan challenge in prepubertal major depression. Depressed vs normal children. , 1992, Archives of general psychiatry.
[20] X. Bertagna,et al. Potentiation of the classic ovine corticotrophin releasing hormone stimulation test by the combined administration of small doses of lysine vasopressin , 1993, Clinical endocrinology.
[21] F A Mussa-Ivaldi,et al. Adaptive representation of dynamics during learning of a motor task , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[22] L. Kar,et al. Serotonergic regulation of renin and prolactin secretion , 1995, Behavioural Brain Research.
[23] T. Dinan,et al. Serotonin and the regulation of hypothalamic-pituitary-adrenal axis function. , 1996, Life sciences.
[24] H. Westenberg,et al. Behavioral, neuroendocrine and biochemical effects of different doses of 5-HTP in panic disorder , 1996, European Neuropsychopharmacology.
[25] H Derendorf,et al. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. , 1997, International journal of clinical pharmacology and therapeutics.
[26] F. Cavagnini,et al. Dopamine infusion enhances the adrenocorticotropic hormone and cortisol response to metoclopramide in hyperprolactinemic patients but not in normal subjects. , 1997, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[27] S. Sekiya,et al. Corticotrophin and vasopressin responses to metoclopramide in patients with hypothalamic amenorrhoea , 1997, Clinical endocrinology.
[28] F. Mussa-Ivaldi,et al. The motor system does not learn the dynamics of the arm by rote memorization of past experience. , 1997, Journal of neurophysiology.
[29] T. Dinan,et al. Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression. , 1998, Life sciences.
[30] P. Cowen,et al. Brain 5-HT neurotransmission during paroxetine treatment , 1998, British Journal of Psychiatry.
[31] M. Ferrari,et al. Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers. , 1998, Journal of clinical psychopharmacology.
[32] Desmopressin normalizes the blunted adrenocorticotropin response to corticotropin-releasing hormone in melancholic depression: evidence of enhanced vasopressinergic responsivity. , 1999, The Journal of clinical endocrinology and metabolism.
[33] T. Dinan,et al. Desmopressin augments pituitary–adrenal responsivity to corticotropin-releasing hormone in subjects with chronic fatigue syndrome and in healthy volunteers , 1999, Biological Psychiatry.
[34] G. Aguilera,et al. Vasopressinergic regulation of the hypothalamic–pituitary–adrenal axis: implications for stress adaptation , 2000, Regulatory Peptides.
[35] T. Endo,et al. Neurochemistry and neuropharmacology of emesis - the role of serotonin. , 2000, Toxicology.
[36] N. Danbolt. Glutamate uptake , 2001, Progress in Neurobiology.
[37] Carmine M Pariante,et al. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment , 2001, Biological Psychiatry.
[38] A. Kjaer,et al. Serotonergic Stimulation of Corticotropin‐Releasing Hormone and Pro‐Opiomelanocortin Gene Expression , 2002, Journal of neuroendocrinology.
[39] R. Elliott,et al. 5-HT2C receptor activation by m-chlorophenylpiperazine detected in humans with fMRI , 2002, Neuroreport.
[40] J. V. van Gerven,et al. Placebo-Controlled Comparison of Three Dose-Regimens of 5-Hydroxytryptophan Challenge Test in Healthy Volunteers , 2002, Journal of clinical psychopharmacology.
[41] N. Nicolson,et al. L-5-Hydroxytryptophan induced increase in salivary cortisol in panic disorder patients and healthy volunteers , 2002, Psychopharmacology.
[42] K. Schruers,et al. Acute l-5-hydroxytryptophan administration inhibits carbon dioxide-induced panic in panic disorder patients , 2002, Psychiatry Research.
[43] T. Dinan,et al. Vasopressin as a target for antidepressant development: an assessment of the available evidence. , 2002, Journal of affective disorders.